Ublituximab for early relapsing multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsing multiple sclerosis (MS) in the last 5 years.
- You are between 18 and 70 years old.
- You have a low level of disability (EDSS score less than 2.5).
- Your MRI shows fewer than 10 MS lesions.
- You have not taken certain strong MS drugs or B-cell depleting therapies before.
- You are willing to receive ublituximab infusions and attend all study visits for 96 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
This trial tests an oral drug called remibrutinib to see if it can help people with relapsing or progressive multiple sclerosis. It uses brain scans (MRI) to track how well the drug works.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.